News

Lupin announced that the 44th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Lupin has allotted 2,358 equity shares under ESOP on 08 July 2026. With this allotment, the paid up equity share capital has increased to Rs 91,44,69,788 consisting of 45,72,34,894 equity shares of Rs 2/- each.

Lupin today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6�C11 years, weighing at least 20 kg), adolescents (12�C17 years), and adults (��18 years) with non-dystrophic myotonic disorder.

Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Enzalutamide Tablets, 40 mg, 80 mg, 120 mg, and 160 mg. The U.S. FDA has tentatively approved Lupin`s Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi� Tablets of Astellas for the indication in the approved labeling. While Xtandi Tablets are traditionally available in 40 mg and 80 mg strengths, Lupin`s tentatively approved 120 mg and 160 mg strengths will provide healthcare providers and patients with alternative dosing options.

Lupin today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec� (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain. This collaboration combines Lupin`s global respiratory expertise and proven pMDI manufacturing excellence and ERN`s robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.